Phase II Study of Sorafenib, Valproic Acid, and Sildenafil in the Treatment of Recurrent Glioblastoma
Phase of Trial: Phase II
Latest Information Update: 10 May 2017
At a glance
- Drugs Sildenafil (Primary) ; Sorafenib (Primary) ; Valproic acid (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 27 May 2015 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018, as reported by ClinicalTrials.gov.
- 03 Apr 2013 Planned number of patients changed from 51 to 66 as reported by ClinicalTrials.gov.
- 03 Apr 2013 Planned initiation date changed from 1 Mar 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.